FLT3-ITD Targeted Therapy in Fit AML Patients

NCT07425808 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

230

Enrollment

NETWORK

Sponsor class

Conditions

AML (Acute Myeloid Leukemia)

Interventions

DRUG: Gilteritinib
DRUG: Venetoclax
DRUG: Azacitidine (AZA)
DRUG: Local standard of care (SOC)

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC

Collaborators

[object Object]
[object Object]